Clinical Trials Directory

Trials / Completed

CompletedNCT03686059

Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease

Outcome of Concomitant Use of Punctal Plugs and Omeg 3 Fatty Acids on Ocular Surface Disease in Patients Using Systemic Isotretinoin

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
90 (actual)
Sponsor
Benha University · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Ocular surface disease is a common adverse effect of systemic isotretinoin therapy. The investigators consider that punctal plugs and Omega 3 is a good line for treatment of ocular surface disease associated with systemic isotretinoin therapy

Detailed description

Subjective and objective evaluation of ocular surface disease was done at baseline ,1 and 3 months of the study .

Conditions

Interventions

TypeNameDescription
DRUGOmega 3daily intake of 250 mg
DEVICEpunctal plugpunctal plug will be inserted in inferior punctum

Timeline

Start date
2018-07-02
Primary completion
2019-11-15
Completion
2019-11-20
First posted
2018-09-26
Last updated
2019-11-26

Locations

1 site across 1 country: United Arab Emirates

Source: ClinicalTrials.gov record NCT03686059. Inclusion in this directory is not an endorsement.

Outcome of Omega 3 FA and Punctal Plugs on Ocular Surface Disease (NCT03686059) · Clinical Trials Directory